摘要
目的观察比较不同剂量氟维司群治疗雌激素受体阳性晚期乳腺癌患者的临床效果。方法选取医院接受治疗的雌激素受体阳性晚期乳腺癌患者108例,随机分为对照组和观察组,每组54例。对照组给予低剂量氟维司群治疗,观察组给予高剂量氟维司群治疗,比较2组患者治疗效果及不良反应发生情况。结果 2组患者治疗效果及各项不良反应发生率比较差异均无统计学意义(P> 0. 05)。结论氟维司群可有效改善雌激素受体阳性晚期乳腺癌患者预后,不同剂量疗效一致,安全性较佳,值得推广应用。
Objective To compare the clinical effects of different doses of fulvestrant in the treatment of patients with estrogen receptor-positive advanced breast cancer.Methods One hundred and eight patients with estrogen receptor-positive advanced breast cancer were randomly divided into control group and observation group,with 54 cases in each group.The control group was treated with low-dose fulvestrant,and the observation group was treated with high-dose fulvestrant.The treatment effect and adverse reactions of the two groups were compared.Results There was no significant difference in the treatment effect and incidence of adverse reactions between the two groups(P>0.05).Conclusion Fulvestrant can effectively improve the prognosis of patients with estrogen receptor-positive advanced breast cancer,and the efficacy and safety of different doses are consistent,which is worthy of popularization and application.
作者
张鹏程
罗琴
ZHANG Pengcheng;LUO Qin(Department of Thyroid and Breast Surgery,Xiangyang First People's Hospital Affiliated to Hubei Medical College,Xiangyang City,Hubei 441000,China)
出处
《临床合理用药杂志》
2019年第26期12-13,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
晚期乳腺癌
氟维司群
不同剂量
Advanced breast cancer
Fluvial group
Different doses
